Received Nov 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPHEPBIP | DTAP + HEPB + IPV (PEDIARIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | A32BB | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
off schedule for Hepatitis B; late hepatitis B as her first dose of Hepatitis B was on 5-Aug-2019; inadvertently received Pediarix instead of Kinrix on 15-MAY-2025; This non-serious case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too long in a 6-year-old female patient who received DTPa-HBV-IPV (Pediarix) (batch number A32BB, expiry date 10-AUG-2025) for prophylaxis. Co-suspect products included DTPa-IPV (Kinrix) for prophylaxis and HBV (Engerix B) for prophylaxis. Previously administered products included Hepatitis b (received 1st dose of vaccine on an unknown date). On 15-MAY-2025, the patient received Pediarix. The patient did not receive Kinrix. On 16-JUL-2025, the patient received Engerix B. On 15-MAY-2025, an unknown time after receiving Pediarix the patient experienced drug dose administration interval too long (Verbatim: late hepatitis B as her first dose of Hepatitis B was on 5-Aug-2019) and wrong vaccine administered (Verbatim: inadvertently received Pediarix instead of Kinrix on 15-MAY-2025). On 16-JUL-2025, an unknown time after receiving Engerix B the patient experienced drug dose administration interval too short (Verbatim: off schedule for Hepatitis B). The outcome of the drug dose administration interval too long, wrong vaccine administered and drug dose administration interval too short were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date : 24-JUL-2025 A 6 year old patient inadvertently received Pediarix instead of Kinrix on 15th May 2025 which led to wrong vaccine administered. Pediarix was the patient 3rd dose of DTaP, 4th dose of IPV and 2nd dose of Hepatitis B (late hepatitis B as her first dose of Hepatitis B was on 5-Aug-2019-Brand unspecified which led to drug dose administration interval too long for hepatitis b antigen. Since then the patient received a 3rd dose of Hepatitis B (Engerix-B) on 16th July 2025 which led to drug dose administration interval too short for hepatitis b antigen.